发布时间
2026/03/25 04:5812 分钟前源站更新
2026/03/25 04:5812 分钟前首次抓取
2026/03/25 04:5812 分钟前发布时间
12 分钟前源站更新
12 分钟前首次抓取
12 分钟前用于追踪这条内容的来源与记录标识。
Source
原始链接
发布时间
2026/03/25 04:5812 分钟前源站更新
2026/03/25 04:5812 分钟前首次抓取
2026/03/25 04:5812 分钟前发布时间
12 分钟前源站更新
12 分钟前首次抓取
12 分钟前用于追踪这条内容的来源与记录标识。
Source
原始链接
Eli Lilly profits more than double as weight-loss revenue soars
发布时间
161 天前
2026-04-30 19:37:18 UTC
源站更新
161 天前
2026-04-30 19:37:19 UTC
首次抓取
161 天前
2026-04-30 12:16:48 UTC
礼来公司第一季度利润翻倍，主要受糖尿病药物 Mounjaro 和减肥药 Zepbound 销量大增推动。公司上调了 2026 年业绩指引，其新推出的减肥药丸 Foundayo 已吸引 2 万名用户。
Eli Lilly's first-quarter profits more than doubled, driven by surging sales of Mounjaro and Zepbound. The company raised its 2026 guidance and reported that 20,000 people have already started using its new weight-loss pill, Foundayo, since its April launch.
用于追踪这条内容的来源与记录标识。
